Prognostic Implications of<sup>68</sup>Ga-FAPI-46 PET/CT–Derived Parameters on Overall Survival in Various Types of Solid Tumors

Masao Watanabe(Juntendo University Urayasu Hospital), Manuel Weber(Essen University Hospital), Stefan Kasper(Essen University Hospital), Hong Grafe(Essen University Hospital), Bastian von Tresckow(University of Cologne), Kim M. Pabst(West German Heart and Vascular Center Essen), Wolfgang P. Fendler(Essen University Hospital), Helena Lanzafame(Essen University Hospital), Fadi Zarrad(Essen University Hospital), Martin Stuschke(Essen University Hospital), Jens T. Siveke(German Cancer Research Center), Céline Lugnier(Ruhr University Bochum), Hubertus Hautzel(Deutsches Konsortium für Translationale Krebsforschung), Nader Hirmas(German Breast group), Boris Hadaschik(Essen University Hospital), Rainer Hamacher(Essen University Hospital), Clemens Aigner(Comprehensive Cancer Center Vienna), Viktor Grünwald(Deutsche Schmerzgesellschaft), Sherko Kümmel(Kliniken Essen-Mitte), Ken Herrmann(Essen University Hospital)
Journal of Nuclear Medicine
May 23, 2024
10.2967/jnumed.123.266981
Cited by 18

Related Papers

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
|The Lancet Oncology|2007|808
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802